SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Curis, Inc. - CRISPRNewsWire • 04/25/22
Curis Announces FDA Partial Clinical Hold for TakeAim Lymphoma Study of Emavusertib (CA-4948)PRNewsWire • 04/11/22
Curis Announces FDA Partial Clinical Hold for TakeAim Leukemia Study of Emavusertib (CA-4948)PRNewsWire • 04/04/22
Curis Announces Gastroenterology Publication of Encouraging Preclinical Data of Emavusertib in Pancreatic CancersPRNewsWire • 03/07/22
Curis Inc. (CRIS) CEO James Dentzer on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 02/25/22
Curis to Release Fourth Quarter 2021 Financial Results and Hold Conference Call on February 24, 2022PRNewsWire • 02/17/22
Curis Announces Updated Data with Additional Encouraging Clinical Activity in Phase 1/2 Study of CA-4948 Monotherapy in Targeted Patients with Relapsed or Refractory AML and MDS; and Initial Clinical Data from Phase 1 Study of CI-8993 in Patients with RelPRNewsWire • 01/06/22
Curis Adds Three New Executives to Management Team Strengthening Medical Affairs, Clinical Development and Clinical OperationsPRNewsWire • 01/03/22
Curis to be Added to the Nasdaq Biotechnology Index and the iShares Biotechnology ETFPRNewsWire • 12/15/21
Here's Why Curis (CRIS) Could be Great Choice for a Bottom FisherZacks Investment Research • 11/24/21
Down 23.2% in 4 Weeks, Here's Why Curis (CRIS) Looks Ripe for a TurnaroundZacks Investment Research • 11/16/21
Curis, Inc. (CRIS) CEO James Dentzer on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/10/21